COVID-19 Coronavirus-Induced Atypical Pneumonia: Efficacy of the Monoclonal Antibody Bevacizumab in Moderate to Severe Cases
Open Access
- 27 September 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Abstract
COVID-19 novel coronavirus has created a global pandemic. Affected patients may develop acute lung injury and its more severe form - acute respiratory distress syndrome. Hypoxia and severe inflammation increase the production of vascular endothelial growth factor (VEGF), which induces vascular endothelial proliferation. Administration of the anti-VEGF monoclonal antibody bevacizumab is proposed for usage in moderate to severe pneumonia. We aim to present two cases of COVID-19 induced atypical pneumonia, which were treated with the anti-VEGF monoclonal antibody bevacizumab.Keywords
This publication has 13 references indexed in Scilit:
- Novel coronavirus disease (COVID‐19) update on epidemiology, pathogenicity, clinical course and treatmentsInternational Journal Of Clinical Practice, 2020
- COVID-19: Current understanding of its Pathophysiology, Clinical presentation and TreatmentPostgraduate Medical Journal, 2020
- Intussusceptive angiogenesis in Covid-19: hypothesis on the significance and focus on the possible role of FGF2Molecular Biology Reports, 2020
- Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and ProgressionPhysiology, 2020
- Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United StatesEmerging Infectious Diseases, 2020
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019Journal of the Chinese Medical Association, 2020
- COVID-19 pathophysiology: A reviewClinical Immunology, 2020
- Pathogenesis of COVID-19 from a cell biology perspectiveEuropean Respiratory Journal, 2020
- Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptorsProceedings of the National Academy of Sciences, 1998